莲芪胶囊联合化疗治疗中晚期食道癌66例临床观察

Clinical Observation of Lianqi Capsule Combined with Chemotherapy in the Treatment of 66 Cases of Advanced Esophageal Cancer

目的：探讨莲芪联合化学治疗（化疗）治疗中晚期食道癌的临床效果。方法：选择笔者所在医院2008年2月～2010年10月期间住院的中晚期食道癌患者130例，随机分为对照组和治疗组，分别64例、66例，两组均应用化疗DF方案，同时治疗组加服莲芪胶囊，对照组加服平消胶囊。结果：治疗组临床疗效略高于对照组，但两组总有效率比较差异无统计学意义（P=0.24）。治疗组1年生存率、2年生存率分别为83.07%、55.38%，均显著高于对照组（P值分别为0.043，0.040）。两组治疗后CD4＋、CD4＋/CD8＋值、NK细胞均较治疗前增高。但治疗组各项指标增高幅度显著，与对照组比较差异均具有统计学意义（P〈0.05）。结论：中晚期食道癌治疗在化疗基础上应用莲芪胶囊，不但能增强患者机体免疫功能，还能提高化疗的临床疗效，延长生存期。

To observe the clinical efficacy of Lianqi Capsule combined with chemotherapy in the treatment of 66 cases of advanced esophageal cancer.Methods：130 patients with advanced esophageal cancer in the hospital where the author in from February 2008 to October 2010 were randomly divided into control and treatment groups. Each group had 64 cases and 66 cases respectively. Both groups were given DF chemotherapy programs, while treatment group were given additional Lianqi capsules and the control group were given additional Pingxiao capsules.Results：The clinical efficacy of the treatment group was slightly higher than that of the control group, but there was no significant difference between the total effective rate （P=0.24）.The 1-year and 2-year survival rates of the treatment group were 83.07% and 55.38%,which were significantly higher than that of the control group（P=0.043 ＆ 0.040）.The value of CD4＋,CD4＋/CD8＋ and the number of NK cells was higher after treatment. The indexes of the treatment group increased significantly compared with the control group,and there were statistically significant differences （P〈0.05）.Conclusion：The therapy that chemotherapy combined with Lianqi Capsules in the treatment of advanced esophageal cancer can not only enhance immune function in patients, but also improve the clinical efficacy of chemotherapy and prolong survival.